Generalizability of sodium-glucose co-transporter-2 inhibitors cardiovascular outcome trials to the type 2 diabetes population: a systematic review and meta-analysis

BACKGROUND: Cardiovascular outcome trials of sodium-glucose co-transporter-2 inhibitors (SGLT2i CVOTs) found the agents to be associated with clinical benefits in terms of cardiovascular and renal outcomes. We performed a meta-analysis to assess and compare the overall prevalence of eligibility for...

Descripción completa

Detalles Bibliográficos
Autores principales: Castellana, Marco, Procino, Filippo, Sardone, Rodolfo, Trimboli, Pierpaolo, Giannelli, Gianluigi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293778/
https://www.ncbi.nlm.nih.gov/pubmed/32534590
http://dx.doi.org/10.1186/s12933-020-01067-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293778/
https://www.ncbi.nlm.nih.gov/pubmed/32534590
http://dx.doi.org/10.1186/s12933-020-01067-8

Ejemplares similares